Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Insulin, Glulisine, Human

Known as: insulin, Lys(B3)-Glu(B29)-, glulisine insulin, INSULIN GLULISINE 
A drug used to control the amount of sugar in the blood of patients with diabetes mellitus. It is a form of the hormone insulin that is made in the… Expand
National Institutes of Health

Related topics

Related topics

13 relations
3 ML Insulin, Glulisine, Human 100 UNT/ML Pen Injector3 ML Insulin, Glulisine, Human 100 UNT/ML Pen Injector [Apidra]Decreased Lipolysis [PE]Diabetes Mellitus, Insulin-Dependent
Expand

Narrower (1)

Apidra

Broader (2)

Hypoglycemic AgentsInsulin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2…
OBJECTIVE To provide evidence-based options on how to intensify basal insulin, we explored head-to-head prandial interventions in… Expand
  • table 1
  • table 2
  • figure 1
  • figure 1
  • table 3
Highly Cited
2013
Highly Cited
2013
Randomized Study Comparing a Basal-Bolus With a Basal Plus Correction Insulin Regimen for the Hospital Management of Medical and Surgical Patients With Type 2 Diabetes
OBJECTIVE Effective and easily implemented insulin regimens are needed to facilitate hospital glycemic control in general medical… Expand
  • figure 1
  • table 1
  • table 2
Highly Cited
2012
Highly Cited
2012
A Randomized Trial of Two Weight-Based Doses of Insulin Glargine and Glulisine in Hospitalized Subjects With Type 2 Diabetes and Renal Insufficiency
OBJECTIVE Renal insufficiency may increase the risk of hypoglycemia in hospitalized patients with diabetes who are treated with… Expand
  • table 1
  • figure 2
  • figure 1
Highly Cited
2011
Highly Cited
2011
Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept’ study
Aim: Stepwise intensification of insulin treatment to match the progressive decline of endogenous insulin secretion has been… Expand
Highly Cited
2010
Highly Cited
2010
Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling
Aims/hypothesisFive insulin analogues, with modified insulin-like molecular structures, are currently approved for treating… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2010
Highly Cited
2010
Insulin Reciprocally Regulates Glucagon Secretion in Humans
OBJECTIVE We tested the hypothesis that an increase in insulin per se, i.e., in the absence of zinc, suppresses glucagon… Expand
  • figure 1
  • figure 2
Highly Cited
2009
Highly Cited
2009
Insulin Analogs Versus Human Insulin in the Treatment of Patients With Diabetic Ketoacidosis
OBJECTIVE To compare the safety and efficacy of insulin analogs and human insulins both during acute intravenous treatment and… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
Review
2008
Review
2008
Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glulisine
Insulin glulisine injection [3B-Lys, 29B-Glu-human insulin] is the newest human insulin analogue product for the control of… Expand
Highly Cited
2008
Highly Cited
2008
Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single‐dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs
Aim:  To investigate whether the addition of a single bolus of insulin glulisine (glulisine), administered at either breakfast or… Expand
Highly Cited
2005
Highly Cited
2005
Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine.
OBJECTIVE To compare the efficacy and safety of insulin glulisine (GLU), a new rapid-acting insulin analogue, injected 0 to 15… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE